

RECEIVED  
#6

MAY 22 2001

TECH CENTER 1800/2900

09/771,536



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of: ) Group Art Unit: 1646  
)  
LANGRIDGE, William H.R. et al. ) Examiner: To be assigned  
)  
Serial No. 09/771,536 )  
)  
Filing Date: January 29, 2001 )  
)  
For: Transgenic Plant-Based Vaccines ) Pasadena, California

---

INFORMATION DISCLOSURE STATEMENT

Box Patent  
Assistant Commissioner for Patents  
Washington, D. C. 20231

Dear Sir:

Attached hereto is one PTO-1449 form listing documents believed relevant to the subject application. It is respectfully requested that these documents be considered by the Examiner and an initialed copy of each form be returned to the undersigned. It should be noted the word "prior" has been deleted from the form.

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE  
U.S. POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO:  
BOX PATENT, ASSISTANT COMMISSIONER FOR PATENTS,  
WASHINGTON, D.C. 20231 ON MAY 14, 2001

BY: ELAINE PORTER

Elaine Porter

RECEIVED

MAY 22 2001

12273-3  
TECH CENTER 1600/2900

09/771,536

Additionally, we would like to inform the Patent and Trademark Office that in a case that has now been considered to be related to the above-identified United States patent application, United States patent application serial no. 09/296,081, should be considered by the Examiner. An Information Disclosure Statement was filed by the law firm previously responsible for that case on August 24, 1999, a copy of which is attached. We do not have copies of the overwhelming majority of the references cited in that Information Disclosure Statement and have been unable to obtain them from the law firm previously responsible for that case. We request that the Examiner obtain any of the references from the Patent and Trademark Office file for that case. If the Examiner is unable to obtain copies, we will attempt to obtain copies from other sources.

It is believed this disclosure complies with the requirements of 37 C.F.R. 1.56 and the Manual of Patent Examining Procedures Section 707.05(b). If for some reason the Examiner considers otherwise, it is respectfully requested the undersigned be called so any deficiencies can be remedied.

A copy of each document is enclosed. Some of the documents may have markings thereon. No significance is meant to be attached to the markings. These documents are not necessarily analogous art.

No fee is believed due in connection with this communication. If, however, any fee is owed, the Commissioner is hereby authorized to charge payment of the fee associated

09/771,536


12273-3

with this communication to Deposit Account No. 19-2090.

Respectfully submitted,

SHELDON & MAK  
a Professional Corporation

Date: May 14, 2001

By   
David A. Farah, M.D.  
Reg. No. 38,134

SHELDON & MAK  
225 South Lake Avenue, Suite 900  
Pasadena, California 91101  
626/796-4000